KSQ Stock
HealthTechLooking to sell KSQ stock or options?
KSQ is a pioneer in the development of transformative medicines, specifically designed to accurately identify the most effective nodal targets of a disease. KSQ's proprietary industrialized functional genomics engine employs a unique set of CRISPR/Cas9 tools that can unveil new pathways and targets in oncology and immuno-oncology. This enables KSQ to discover innovative drug targets, understand the mechanisms driving drug efficacy, and develop groundbreaking single-agent and combination therapies that have the potential to improve patient outcomes.
The Invus Group, Chimera Capital, Polaris Partners, ARCH Venture Partners, Cowen Healthcare Investments, Alpha Wave Global, Flagship Pioneering, Lilly Asia Ventures, Curie.Bio, Monroe Capital, Alexandria Real Estate Equities, Baillie Gifford.